ELISpot and FluoroSpot Assay Market
Number of pages: 100 | Report Format: PDF | Published date: March 23, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 265.0 million |
|
Revenue forecast in 2031 |
US$ 491.3 million |
|
CAGR |
7.1% |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Product, Application, End User, and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global ELISpot and FluoroSpot assay market was valued at US$ 265.0 million in 2022 and is expected to register a revenue CAGR of 7.1% to reach US$ 491.3 million by 2031.
ELISpot and FluoroSpot Assay Market Fundamentals
ELIspot and FluoroSpot can detect released cytokines and quantify the frequency of single cells that generate two cytokines or other effector chemicals simultaneously. They assist in saving cell material and measuring co-expressed cytokines. The cytokine ELISpot is a quantitative and qualitative test that uses the enzyme-linked immunosorbent method to count cytokine-secreting cells. It is exceptionally sensitive and effectively detects low-frequency cytokine-secreting cells (1/300 000). The cytokine generated in response to antigen may be mapped to a single cell, allowing the frequency of T cell responders to be estimated. Cells can be stimulated directly in the anti-cytokine antibody-coated plate (direct assay) or pre-stimulated and then transferred to the pre-coated plate (indirect assay). Once completed, the plates can be evaluated using a plate reader. The test has recently been switched to a FluoroSpot assay, which utilizes fluorochrome-conjugated detection antibodies, allowing for the simultaneous detection of numerous different cytokines and subsequent T cell sub-population analysis.
The cytokine ELISpot assay has been used successfully in a variety of immunology disciplines, including organ transplantation, cancer research, infectious diseases, vaccine development, and autoimmune diseases, where the sensitivity of these assays has been demonstrated to be very useful in detecting autoreactive cells, which typically occur at low frequencies. Both the ELISpot and FluoroSpot assays are commonly employed in clinical trial immuno-monitoring, where quantitative data and T-cell phenotypic characterization at the single-cell level are quite useful. ELISpot’s widespread use over the last decades may be ascribed mostly to its exceptional sensitivity, ease of installation, and resilience. Furthermore, the approach differs little in examining a wide range of cytokines, antibodies, and other secreted proteins, such as chemokines and apolipoproteins.
[7967]
ELISpot and FluoroSpot Assay Market Dynamics
The major factors contributing to the revenue growth of the ELISpot and FluoroSpot assay market are rising vaccine research to combat the drug-resistant strains challenge, the increasing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits. According to the Globocan 2020 information sheet, an estimated 19,292,789 new cancer cases were diagnosed globally, with almost 9,958,133 cancer deaths worldwide. Furthermore, according to the International Agency for Research on Cancer, the global cancer burden will rise to 27.5 million new cancer cases and 16.3 million deaths by 2040. The rising number of cancer patients will likely fuel demand for ELISpot and FluoroSpot test market. Furthermore, according to a World Health Organization (WHO) update from April 2021, noncommunicable diseases (NCDs) kill 41 million people each year, accounting for 71% of all deaths globally, and more than 15 million people die from an NCD between the ages of 30 and 69 years; 85% of these premature deaths occur in low- and middle-income countries. Thus, the prevalence of chronic illnesses would rise, boosting market business opportunities.
ELISpot is important in developing vaccines for various diseases, including AIDS, TB, HIV, malaria, cancer, and influenza. The ELISpot test is one of the most often used immunoassays in clinical trials to evaluate vaccinations. This reputation was built mostly on the sample’s greater sensitivity, statistical read-out, and convenience in mass screening and individual testing. The test may evaluate T-cell responses and vaccine-specific antibody-producing B cells.
ELISpot and FluoroSpot Assay Market Ecosystem
The global ELISpot and FluoroSpot assay market has been analyzed from four perspectives: product, application, end user, and region.
ELISpot and FluoroSpot Assay Market by Product
[96786]
Based on product, the global ELISpot and FluoroSpot assay market has been segmented into analyzers, assay kits, and ancillary products.
The assay kits segment is expected to dominate the market during the forecast period. The increased prevalence of chronic disease and technological advancements in test kits and analyzers fuel market expansion. Furthermore, one of the primary reasons supporting the segment’s revenue growth throughout the forecast period is the increasing usage of these goods for vaccine manufacture in clinical trials. According to the World Health Organization, the main chronic illnesses today account for nearly 60% of all fatalities and 43% of the global disease burden.
According to December 2020, statistics by WHO, primary chronic diseases account for about 60% of all mortality and 43% of the global disease burden. Their impact is expected to rise to 73% of all deaths and 60% of global morbidity by 2020. Furthermore, chronic illnesses account for 79% of mortality in underdeveloped nations. Furthermore, technical advancements in ELISpot and FluoroSpot test kits and analyzers are projected to fuel market expansion.
ELISpot and FluoroSpot Assay Market by Application
Based on application, the global ELISpot and FluoroSpot assay market has been segmented into research and diagnostics. The research segment includes vaccine development, clinical trial, and cancer research. Moreover, the diagnostics segment is also sub-segmented into infectious diseases and transplants.
The diagnostics application is projected to account for a significant revenue share during the forecast period. This is owing to the expanding prevalence of infectious illnesses and chronic sickness globally and the increasing usage of ELISpot tests for disease diagnosis.
ELISpot and FluoroSpot Assay Market by End User
Based on end user, the global ELISpot and FluoroSpot assay market has been segmented into hospitals & clinical labs, biopharmaceutical companies, and research institutes.
The hospitals & clinical labs segment is likely to dominate the market during the forecast period. This is due to a highly targeted population of hospital-preferred patients, particularly in developing countries, an increase in the number of hospital procedures, a greater emphasis in hospitals on the effective and early detection of diseases, and an improvement in the efficiency of diagnostic applications. Furthermore, increasing cancer-related research studies undertaken in hospitals will likely drive hospital market revenue growth.
The biopharmaceutical companies segment is expected to register revenue growth at a higher CAGR throughout the predicted period. There is a rising emphasis on research and related investment to meet the enormous demand for biopharmaceuticals. The ability of biopharmaceutical firms to cure previously incurable diseases has led to the introduction of innovative pharmaceuticals to the market. These factors are expected to help in the revenue growth of the market over the forecast period.
ELISpot and FluoroSpot Assay Market by Region
Based on region, the global ELISpot and FluoroSpot assay market has been segmented into: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America will likely lead the global ELISpot and FluoroSpot assay market throughout the projection period. This is due to the increasing prevalence of chronic conditions, such as infectious diseases, and the aging population. According to the Globocan 2020 study, the United States will have an estimated 2,281,658 new cancer cases in 2020. Moreover, the United States experienced the most prevalent malignancies, such as breast cancer (253,465), lung cancer (227,875), prostate cancer (209,512), and colon cancer (101,809). Compared to other developed nations, the United States has one of the highest prevalence of chronic diseases, including cancer and cardiovascular disease, which may substantially influence the revenue growth of the analyzed market in the country. Chronic illnesses, such as heart disease, cancer, and diabetes, are the leading causes of death and disability in the United States, according to the Centers for Disease Control and Prevention. They are also the primary drivers of the US$3.8 trillion yearly healthcare spending. Thus, increased chronic illness prevalence and rising healthcare spending will improve the country’s market throughout the anticipated period.
Europe was the second-largest market for ELISpot and FluoroSpot tests in terms of revenue share. Increasing product approvals, rising awareness, multiple manufacturers implementing expansion strategies in various regions to broaden their global footprint, strategic acquisition of local and medium-sized manufacturers to improve product portfolio, and expanding R&D operations are expected to drive market revenue growth in Europe. The rise of developing nations, such as South Korea, China, and India, the large population pool, and the growing number of partnerships for life science research projects are some of the important drivers for revenue growth in this regional market.
The Asia Pacific market is predicted to increase considerably throughout the projected period. This is due to a rise in the number of assay kit manufacturers, mergers and acquisitions, and investments in healthcare facilities.
ELISpot and FluoroSpot Assay Market Competitive Landscape
The ELISpot and FluoroSpot assays market is relatively competitive, with a few large competitors. Few big firms presently dominate the industry in terms of market revenue share. Some significant businesses are aggressively using strategies of acquisitions and the launch of new products with other companies to solidify their market positions worldwide.
The prominent players in the global ELISpot and FluoroSpot assay market include:
Strategic Developments
ELISpot and FluroSpot can detect released cytokines and quantify the frequency of single cells that generate two cytokines or other effector chemicals simultaneously. They assist you in saving cell material and measuring co-expressed cytokines. The cytokine ELISPOT is a quantitative and qualitative test that uses the enzyme-linked immunosorbent method to count cytokine-secreting cells.
North America is the key revenue growth region in the global ELISpot and FluoroSpot assay market.
The ELISpot and FluoroSpot assay industry is expected to reach 491.3 million by 2031.
The ELISpot and FluoroSpot assay market is expected to register a revenue CAGR of 7.1% during the forecast period.
The prominent players in the global ELISpot and FluoroSpot assay market include Oxford Immunotec, Cellular Technologies, and Mabtech.
*Insights on financial performance are subject to the availability of information in the public domain